Ning-Fang Ma

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 5

Top Topics

Endoplasmic Reticulum Stress

Signaling Pathway

Inflammatory Response

Top Venues

Cell death & disease

Nature communications

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Guangliang Wang, Xiaofeng Zhang, Wei Cheng, Yanxuan Mo, Juan Chen, Zhiming Cao, Xiaogang Chen, Huiqin Cui, Shanshan Liu, Li Huang, Ming Liu, Lei Ma, Ning-Fang Ma
Correction to: CHD1L prevents lipopolysaccharide-induced hepatocellular carcinomar cell death by activating hnRNP A2/B1-nmMYLK axis. Cell death & disease 13 (3) (2022)
Guangliang Wang, Xiaofeng Zhang, Wei Cheng, Yanxuan Mo, Juan Chen, Zhiming Cao, Xiaogang Chen, Huiqin Cui, Shanshan Liu, Li Huang, Ming Liu, Lei Ma, Ning-Fang Ma
CHD1L prevents lipopolysaccharide-induced hepatocellular carcinomar cell death by activating hnRNP A2/B1-nmMYLK axis. Cell death & disease 12 (10) (2021)
Fan-En Kong, Guang-Meng Li, Yun-Qiang Tang, Shao-Yan Xi, Jane Ho Chun Loong, Mei-Mei Li, Hao-Long Li, Wei Cheng, Wen-Jie Zhu, Jia-Qiang Mo, Yuan-Feng Gong, Hui Tang, Yue Zhao, Yan Zhang, Stephianie Ma, Xin-Yuan Guan, Ning-Fang Ma, Mao-Bin Xie, Ming Liu
Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate. Science translational medicine 13 (579) (2021)
Xiaofeng Zhang, Yinshan Bai, Li Huang, Shanshan Liu, Yanxuan Mo, Wei Cheng, Guangliang Wang, Zhiming Cao, Xiaogang Chen, Huiqing Cui, Ling Qi, Lei Ma, Ming Liu, Xin-Yuan Guan, Ning-Fang Ma
CHD1L augments autophagy-mediated migration of hepatocellular carcinoma through targeting ZKSCAN3. Cell death & disease 12 (10) (2021)
Wei Cheng, Hao-Long Li, Shao-Yan Xi, Xiao-Feng Zhang, Yun Zhu, null Le Xing, Yan-Xuan Mo, Mei-Mei Li, Fan-En Kong, Wen-Jie Zhu, Xiao-Gang Chen, Hui-Qing Cui, Zhi-Ming Cao, Yuan-Feng Gong, Yun-Qiang Tang, Yan Zhang, Xin-Yuan Guan, Ning-Fang Ma, Ming Liu
Growth differentiation factor 1-induced tumour plasticity provides a therapeutic window for immunotherapy in hepatocellular carcinoma. Nature communications 12 (1) (2021)